Introduction
Cytochrome P450 26A1 and 26B1 are members of the cytochrome P450 superfamily that are responsible for the metabolism of retinoic acid (Ray et al., 1997; Guengerich, 2006; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Ross and Zolfaghari, 2011) . They are widely expressed throughout the adult human body, though CYP26A1 is the primary isoform expressed in the adult liver, with little to no hepatic expression of CYP26B1 observed (Xi and Yang, 2008; Thatcher and Isoherranen, 2009; Thatcher et al., 2010; Topletz et al., 2012) . CYP26B1 mRNA expression has been reported to be highest in the adult brain (White et al., 2000; Thatcher and Isoherranen, 2009; Topletz et al., 2012) . Additional sites of expression for CYP26A1 mRNA include the skin, testes, kidney, and lung, while CYP26B1 mRNA has been identified in skin, lung, testes, placenta, ovaries and intestine (Xi and Yang, 2008; Osanai and Lee, 2011; Topletz et al., 2012) . While the enzymes generally exhibit the highest degree of activity towards all trans-retinoic acid (at-RA), they also metabolize other retinoic acid isomers, albeit with lower activities (White et al., 1996; White et al., 2000; Taimi et al., 2004; Ross and Zolfaghari, 2011) .
CYP26A1 and CYP26B1 also metabolize retinoic acid metabolites 4-hydroxy-at-RA, 4-oxo-at-RA and 18-hydroxy-at-RA (Lutz et al., 2009; Shimshoni et al., 2012; Topletz et al., 2012; Topletz et al., 2014) .
Retinoic acid signaling and altered retinoic acid concentrations play a role in various disease states (Miller, 1998; Kuenzli and Saurat, 2001; Njar, 2002; Ahmad and Mukhtar, 2004; Njar et al., 2006; Verfaille et al., 2008) . As a result, the design and synthesis of inhibitors of CYP26 activity has received great interest in recent years. While inhibitors of CYP26 have been identified, the role of these enzymes in the metabolism of xenobiotics remains unclear. Of special interest are the synthetic retinoic acid receptor agonists that are structurally similar to retinoic acid and have moieties amenable to oxidative metabolism. One such retinoid is tazarotene, an acetylene-containing compound that is administered topically for stable plaque psoriasis or mild acne (Tang-Liu et al., 1999) . Tazarotene is a pro-drug with its activity being attributed to an active metabolite, tazarotenic acid, which binds with a high affinity to the retinoic acid receptors (Chandraratna, 1996) . The active metabolite shares key structural features with at-RA and has been reported to be metabolized by a number of drug metabolizing enzymes including 6 CYP2C8, CYP3A4, FMO1 and FMO3 (Madhu et al., 1997; Tang-Liu et al., 1999; Attar et al., 2003; Attar et al., 2005) . Whether tazarotenic acid is a substrate of CYP26A1 and CYP26B1 is currently unknown.
In the absence of crystal strucutres, homology modeling is a commonly applied computational technique used to predict protein structure and function (Hillisch et al., 2004; Cavasotto and Phatak, 2009 ). The hypotheses generated by a homology model can be used to assess target druggability, to aid in the rational design of ligands and to predict drug metabolism and toxicity, all of which can then be used to iteratively refine the model (Hillisch et al., 2004) . The flexible and hydrophobic nature of cytochrome P450 active sites often presents a challenge when attempting to use a homology model to accurately predict the site of metabolism for a given substrate (Williams et al., 2000; Lewis, 2002; Eksterowicz et al., 2014) . Several models have been published for CYP26A1 and CYP26B1 and have been successfully used to rationalize the stereoselective product formation of 4-OH-at-RA by CYP26A1 or the binding of triazole-or imidazole-containing inhibitors within the active site of each enzyme (Gomaa et al., 2006; Gomaa et al., 2008; Karlsson et al., 2008; Gomaa et al., 2011a; Gomaa et al., 2011b; Shimshoni et al., 2012; Sun et al., 2015) . There are currently no homology models that compare the structure and function of CYP26A1 and CYP26B1 based on the metabolism of a xenobiotic compound and attempts to crystallize either isoform have been largely unsuccessful.
The aim of this work was to evaluate and characterize the active sites of CYP26A1 and CYP26B1 using homology modeling supported by xenobiotic metabolism data. Models were constructed for each enzyme and compared for structural similarities and differences. at-RA and tazarotenic acid were docked into the active sites and the predicted sites of metabolism evaluated. Metabolite identification experiments were used to confirm the hypotheses generated by the homology models. Finally, in vitro experiments were carried out to compare the metabolism of tazarotenic acid across a panel of drug metabolizing enzymes and to determine the kinetic parameters for the formation of metabolites from tazarotenic acid by CYP26A1 and CYP26B1.
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Materials and Methods
Materials.
Tazarotenic acid and all metabolite standards were obtained from Tocris Chemicals (Bristol, United Kingdom). CYP26A1 was expressed and characterized as previously described (Lutz et al., 2009 ). All other reagents were obtained as noted below. Solvents were from Sigma-Aldrich (St. Louis, MO) and were of the highest grade available.
Sequence verification and expression of CYP26B1. To express recombinant CYP26B1, the human CYP26B1 cDNA was obtained from OriGene Technologies (Rockville, MD) (catalog number TC120799). Upon sequencing of the obtained clone, two single nucleotide polymorphisms were discovered that differed from the sequence reported in NCBI (Q9NR63). The two SNPs were an A191G conversion resulting in an H>R amino acid change and a G788A conversion resulting in a G>S amino acid change (CYP26B1*1, Figure 1 ). To determine which of the possible SNPs would be reflective of the CYP26B1 sequence in the human population, genomic DNA was extracted from 12 human livers from the University of Washington human liver bank and the two sections of the CYP26B1 gene were sequenced in all 12 donors. In brief, genomic DNA (50 ng) was amplified by PCR using either forward (5'-TCTTTGAGGGCTTGGATCTG-3') and reverse (5 while adding a 6xHis tag with a TEV cleavage site to maintain similarity with the commercially available clone as previously described (Topletz et al., 2012) . CYP26B1 protein was expressed using the Bac-toBac baculovirus expression system (Life Technologies, Grand Island, NY) in Sf9 cells according to the manufacturer's instructions as described previously (Topletz et al., 2012) . Sf-900 II SFM liquid media (Life Technologies, Grand Island, NY) supplemented with 2.5% fetal bovine serum was used and during protein expression ferric citrate (0.2 mM) and δ -aminolevulinic acid (0.3 mM) were added to the media 24 hours post-infection to facilitate heme synthesis. The cells were harvested 48 hours post infection, washed once in PBS with 1 mM PMSF, pelleted and stored at -80˚C. Membrane fractions containing CYP26B1 were prepared by centrifugation as described previously (Topletz et al., 2012) and P450 content determined via CO-difference spectrum.
IC 50 Determination for Retinoic Acid Receptor Agonists. Six retinoic acid receptor agonists were assessed for in vitro inhibition of CYP26A1 and CYP26B1 catalyzed 9-cis-4-hydroxyretinoic acid formation. Various concentrations of each inhibitor (0 -100 µM) were incubated with 5 pmol CYP26A1 or CYP26B1, 10 pmol cytochrome P450 reductase, and 100 nM 9-cis-retinoic acid in 100 mM potassium phosphate buffer (pH 7.4). Incubations were initiated by the addition of 1 mM NADPH (final concentration) and quenched after 2 minutes (CYP26A1) or 5 minutes (CYP26B1) with 5 volumes of ethyl acetate containing acitretin as an internal standard. All samples were evaporated to dryness under a gentle stream of N 2 , reconstituted in methanol and assayed for 9-cis-4-hydroxyretinoic acid concentrations by HPLC-UV as previously described (Thatcher et al., 2011) . All IC 50 determinations were conducted in triplicate.
Homology Modeling. Homology models of CYP26A1 and CYP26B1 were constructed using Prime (Schrodinger LLC, New York). The amino acid sequence of human CYP26A1 was obtained from the 9 NCBI protein server (GenBank ID: 2688846) and the CYP26B1 amino acid sequence was obtained as described above. CYP120 (crystal structure, pdb 2VE3) was used as the template for both homology models. Compared to CYP120, CYP26A1 had 33% sequence identity and 53% positive sequence coverage while CYP26B1 had 34% sequence identity and 54% positive sequence coverage. The heme prosthetic group was added to each homology model and ligated to Cys442 (CYP26A1) or Cys441 (CYP26B1), followed by energy minimization prior to ligand docking using OPLS_2005 force field constraints as defined within the MacroModel algorithm (Schrodinger LLC, New York). In order to flexibly dock at-RA, tazarotenic acid and tazarotenic acid sulfoxide, a ligand grid (12 x 12 x 12 Å) for which the center of mass of each ligand would be constrained to was defined and centered approximately 2 -3 Å above the heme iron using Glide (Schrodinger LLC, New York). Structural rationalization of each homology model was performed through the evaluation of Ramachandran plots and model assessment of odd bond lengths and angles. Determination of model flexibility was assessed by comparison of helical versus loop motifs and by prediction of 2° structure characteristics using PSIPRED (University College London, UK) and SSPro (Schrodinger). Ligand structures were also minimized using the OPLS_2005 force field constraints within LigPrep (Schrodinger LLC, New York). GlideScore and eModel scoring algorithms were used to assess the docking poses of the ligands within the active site of each enzyme (Friesner et al., 2004; Friesner et al., 2006) . The use of the eModel scoring algorithm allowed for selection of the best docking pose based upon the GlideScore, grid score and ligand score of each docked ligand (Perola et al., 2004) . The hydrogen atoms nearest the heme iron for the at-RA and tazarotenic acid docking poses with the highest GlideScores and eModel scores were used as the predicted sites of oxidative metabolism for each compound. The volume of the active site within each homology model was estimated using DoGSiteScorer (Volkamer et al., 2012 Enzyme Kinetics. In vitro enzyme kinetic parameters were determined for tazarotenic acid metabolite formation using 5 nM CYP26A1 or CYP26B1, 25 nM purified human reductase and 0 -10 µM tazarotenic acid. Incubations were carried out for 10 minutes at 37 ºC to ensure product linearity with regard to time and protein concentration. Additional experiments to determine the kinetic parameters for the sequential metabolism of tazarotenic acid metabolite sulfoxide used substrate concentrations ranging from 0 -50 µM. Samples were prepared as described for in vitro metabolic profiling experiments. 11 (final concentrations) in 100 mM potassium phosphate buffer (pH 7.4). Following a three minute preincubation at 37 ºC, reactions were initiated with the addition of 1 mM NADPH (final concentration).
Identification of the Enzymes
For incubations utilizing flavin-containing monooxygenase enzymes, the pre-incubation step consisted of enzyme and NADPH followed by initiation with substrate due to the known instability of FMOs at 37 ºC in the absence of cofactor (Foti and Fisher, 2004) . Incubations (50 µL, final volume) were carried out for 30 minutes at 37 ºC before being quenched with 3 volumes (v/v) of ice-cold acetonitrile containing tolbutamide as an internal standard. Samples were mixed and sedimented at 1240 x g for ten minutes before being transferred for LC-MS/MS analysis. Data was expressed as the percent of total metabolite formed across the panel of enzymes for each individual metabolite. phase system was used with a Kinetex 2.6 µm C18 100 Å (100 x 2.1 mm) column (Phenomenex, Torrance, CA). A gradient of 2.5% B (0 -3 minutes), 2.5% B -95% B (from 3 -14 minutes), 95% B
LC-MS/MS
(from 14 -17 minutes) followed by re-equilibration at 2.5% B for 3 minutes was used to achieve chromatographic separation of all analytes. Initial metabolite identification experiments used full scan analysis from 100 -800 amu followed by analysis of the corresponding product ion spectra for each This article has not been copyedited and formatted. The final version may differ from this version. applied to all MS analyses included the curtain gas (12 arbitrary units), CAD gas (medium), ion spray voltage (5000 V), source temperature (500 °C) and ion source gas 1 and gas 2 (30 arbitrary units, each).
Data Analysis. Mass spectrometry data was evaluated using Analyst (version 1.5; Applied Biosystems, Foster City, CA). Analyte concentrations were determined by comparing peak areas in unknown samples to those obtained from standard curves with analytical standards (dynamic range: 1 -2000 nM;
weighting: 1/x). Parameter fitting for IC 50 and enzyme kinetic data was performed using Graphpad Prism as described below (version 6.03; Graphpad Software Inc., San Diego, CA).
IC 50 values for retinoic acid receptor agonists in the 9-cis-4-hydroxyretinoic acid assay were determined by nonlinear regression using Equation 1 13
Results
Homology Modeling. Characterization of CYP26B1 from a commercially available clone (OriGene, Rockville, MD) and set of 12 human livers identified two amino acids which differed from the currently accepted amino acid sequence of the enzyme (Figure 1 ). The two sequencing differences were an A191G substitution resulting in an H64R amino acid change and a G778A substitution resulting in a G260S amino acid change. All 12 human donors sequenced had a CYP26B1 sequence identical to the clone obtained from OriGene and did not have the two sequencing differences observed in the previously reported clone of CYP26B1 (UniProtKB Q9NR63). Therefore the sequence with arginine at position 64 and serine in residue 260 was accepted as the wild type sequence of CYP26B1 (CYP26B1*1). The sequence of CYP26B1*1 is shown in Figure 1 and was used to build the subsequent CYP26B1 homology model. In order to assess the active sites of CYP26A1 and CYP26B1, homology models of each enzyme were constructed using the crystal structure of CYP120 (pdb 2VE3), which showed the highest degree of sequence similarity with CYP26A1 or CYP26B1 in a BLAST search. Sequence analysis indicated CYP26A1 had a sequence identity of 44.47% with CYP26B1 (Q9NR63), 44.26% with CYP26B1*1 and 33.26% with CYP120 (2VE3). CYP26B1*1 had a 99.61% sequence identity with CYP26B1 (Q9NR63) and a 34.69% sequence identity with CYP120. Superimposition of the CYP26A1 or CYP26B1 homology models with the template structure (CYP120) resulted in RMSD values of 1.038 and 1.168, respectively.
Superimposition of the CYP26A1 and CYP26B1 homology models with each other resulted in a RMSD value of 1.651. Similarities in hydrophobic binding residues were observed for CYP26A1 and CYP26B1, with W112, Phe222 and Phe299 occupying analogous positions in the CYP26A1 active site as W117, Phe222 and Phe295 in the CYP26B1 active site (Figure 2) . A greater divergence was observed for those amino acid residues potentially capable of stabilizing the carboxylate moiety of at-RA in the active site of CYP26A1 (Arg64, Arg86 and Arg90) and CYP26B1 (W65, Arg76, Tyr372 and Arg373). Parameters detailing the structural evaluation of the template and the model are shown in Table 1 15 heme iron (Table 1) . Arg90 (CYP26A1) and Ser369 or Arg373 (CYP26B1) were located within 3 Å of the carboxylic acid moiety of at-RA. Amino acid residues depicted in Figure 3 and Supplemental Figure   2 are located within 3 Å of the docked at-RA ligand.
In order to select a non-endogenous retinoid-like molecule to include in the homology model analysis, a panel of retinoic acid receptor agonists was screened for inhibitory potency against CYP26A1 and CYP26B1. IC 50 values ranged from 3.7 -18 µM for CYP26A1 and from 0.13 -31 µM for CYP26B1 (Table 2 ). Tazarotenic acid was the second most potent inhibitor from the panel against CYP26A1, the most potent inhibitor against CYP26B1 and the only inhibitor to exhibit low to submicromolar inhibition potency in both assays. No evidence of time dependent inhibition was observed with tazarotenic acid. As such, it was selected for further evaluation in the CYP26A1 and CYP26B1 homology models. Formation of all tazarotenic acid metabolites was NADPH dependent. In order to assess the sequential metabolism of tazarotenic acid by CYP26A1 and CYP26B1, incubations were conducted using tazarotenic acid sulfoxide as the starting material. Both CYP26A1 and CYP26B1 catalyzed the metabolism of tazarotenic acid sulfoxide to tazarotenic acid sulfone (Figure 5b ). No activation of the acetylene moiety was observed in incubations with either enzyme. A proposed metabolic scheme is shown in Figure 6 .
In Vitro Enzyme Kinetics. The enzyme kinetic parameters describing the formation of tazarotenic acid sulfoxide and hydroxytazarotenic acid were determined for CYP26A1 and CYP26B1. Enzyme kinetic parameters were determined using Michaelis-Menten kinetics and are reported in Table 3 
Identification of the Enzymes Responsible for the Oxidative Metabolism of Tazarotenic Acid.
Previous reports evaluating the enzymes responsible for tazarotenic acid metabolism in vitro have implicated CYP2C8, FMO1 and FMO3 in the formation of tazarotenic acid sulfoxide (Attar et al., 2003) .
Using an expanded drug metabolizing enzyme panel and clinically relevant concentrations of tazarotenic acid, additional enzymes were identified that may contribute to the metabolism of tazarotenic acid. The highest rates of tazarotenic acid sulfoxide formation were observed for CYP26A1 and CYP26B1, followed by CYP2C8 and CYP3A7 (Figure 8a) . Formation of the sulfoxide metabolite was also observed in incubations with CYP2C9, CYP2J2, CYP3A4, CYP3A5 and aldehyde oxidase. Minor contributions were noted for CYP1A2 and CYP2B6. No metabolite formation was observed in incubations with FMO1, FMO3 or FMO5. The hydroxylated metabolite of tazarotenic acid was formed primarily by CYP26A1 and CYP26B1, with additional contributions from CYP2C8, CYP3A5 and CYP3A7 ( Figure   8b ). Similar to the formation of tazarotenic acid sulfoxide, trace amounts of the hydroxylated metabolite were also observed in incubations with the majority of the enzymes evaluated in the panel.
Discussion
The CYP26 family of cytochrome P450s (CYP26A1, CYP26B1 and CYP26C1) has been identified as being responsible for the metabolism of at-RA and its metabolites (Ray et al., 1997; Taimi et al., 2004; Guengerich, 2006; Lee et al., 2007; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Helvig et al., 2011; Ross and Zolfaghari, 2011; Nelson et al., 2013) . To date, however, no known xenobiotic compounds have been identified as substrates of CYP26A1 or CYP26B1, the two most characterized CYP26 isoforms. As both enzymes are expressed in human skin and many retinoid-based treatments are administered topically, the potential exists for these CYP26s to contribute to the metabolism and elimination of these compounds (Heise et al., 2006; Osanai and Lee, 2011; Topletz et al., 2012 ).
Furthermore, a major focal point in the development of synthetic retinoids is to overcome the pharmacokinetic shortcomings of at-RA, such as the observed autoinduction of its clearance pathways.
Tazarotene is an acetylenic retinoid which is readily converted via hydrolysis to tazarotenic acid upon topical administration (Duvic, 1997; Madhu et al., 1997; Tang-Liu et al., 1999; Menter, 2000; Yu et al., 2003; Attar et al., 2005; Talpur et al., 2009) . It is prescribed for the treatment of abnormal keratinocyte proliferation, as is observed in patients with stable plaque psoriasis, mild to moderate acne and basal cell carcinoma (Tang-Liu et al., 1999; Talpur et al., 2009 ). The pharmacological mechanism of action described for tazarotene involves metabolism to tazarotenic acid which subsequently binds to retinoic acid receptors, primarily RAR-β and RAR-γ (Chandraratna, 1996) . As an inhibitor of CYP26A1 and CYP26B1, tazarotenic acid may also serve to locally increase concentrations of retinoic acid in the skin, a mechanism that may hold potential in treating dermatological disorders. As such, a greater understanding of the structural characteristics of CYP26A1 and CYP26B1 which lend themselves to the catalytic and inhibitory properties of tazarotenic acid by these enzymes may have significant clinical relevance in terms of developing the next generation of topical pharmaceutics.
Homology models were designed in order to characterize the active site and substrate binding characteristics of CYP26A1 and CYP26B1. Prior to designing the homology models, the wild type gene 19 amino acid residues from the currently available sequence of the enzyme (NCBI Reference Sequence:
NP_063938.1; UniProtKB Q9NR63), which had been isolated from human retinal cDNA (White et al., 2000) . Consistent with the commercially available clone, the amino acid sequence analysis showed that the amino acids residues at position 64 and 260 in the CYP26B1 sequence are an arginine and a serine residue, respectively, as opposed to the histidine and glycine originally reported from the retinal cDNA of a single human donor (Figure 1) . However, as neither of these residues appears to be involved in substrate binding, it is unlikely that they influenced the results of previously published CYP26B1 To apply the model to a xenobiotic ligand, the sites of metabolism of tazarotenic acid, an inhibitor of CYP26, were predicted. When tazarotenic acid was docked in the active sites of CYP26A1 or CYP26B1, a single orientation was observed with the benzothiopyranyl moiety directed toward the heme ( Figure 4A and 4C). A number of the residues that appear to be important in orienting tazarotenic acid in the active sites of CYP26A1 and CYP26B1 have also been reported to be involved in the binding of at-RA in the active sites of these enzymes. For example, Trp112, Phe222, Phe299, Thr304, Pro369 and
Val370 have been proposed to be involved in CYP26A1 binding of both at-RA as well as retinoic acid metabolism blocking agents (RAMBAs) that are able to inhibit the activity of CYP26A1 (Gomaa et al., 2008; Karlsson et al., 2008; Gomaa et al., 2011a; Gomaa et al., 2011b) . Similarly, Trp65, Trp117, Thr121, Phe222, Phe295, Ser369, Val370 and Pro371 have been suggested to be key residues in binding at-RA and other ligands of CYP26B1 (Karlsson et al., 2008; Saenz-Mendez et al., 2012) . Results from metabolite identification studies confirmed the ability of CYP26A1 and CYP26B1 to contribute to the metabolism of tazarotenic acid and tazarotenic acid sulfoxide only at the benzothiopyranyl end of the molecule, and a proposed metabolic scheme is shown in Figure 6 . Enzyme kinetic experiments suggest that the metabolism of tazarotenic acid by CYP26A1 and CYP26B1 represents a rare example of a substrate having higher k cat values for CYP26B1 as compared to CYP26A1. 
